

Online Table A. Studies of Pharmacologic Therapy for Female Sexual Dysfunction

<i>Therapy/dosage</i>	<i>Population</i>	<i>Effects</i>	<i>Adverse effects</i>	<i>Evidence</i>
Transdermal testosterone, 150 to 450 mcg daily (not FDA approved for use in women)	Surgically menopausal women receiving estrogen therapy who have diminished sexual interest or desire	Increased sexual desire, increased satisfaction with sexual activity, decreased personal distress; studies showed effect with a 300-mcg dose	One study showed a statistically significant increase in facial depilation ^{A1} ; no other statistically significant increase in adverse events over six months of treatment; long-term effects are unknown	Blinded, prospective, crossover study with strong placebo response ^{A1} ; double-blind RCTs ^{A2-A5}
Transdermal testosterone, 300 mcg daily (not FDA approved for use in women)	Naturally menopausal women receiving hormone therapy who have diminished sexual interest or desire	Increased satisfaction with sexual activity, increased sexual desire, decreased personal distress	Trend toward increased depilation, increase in facial hair	Double-blind RCT ^{A6}
Testosterone 1% cream, 10 mg daily applied to the thigh (not FDA approved for use in women)	Premenopausal women with decreased serum testosterone levels and decreased sexual self-rating scores	Improved sexual self-rating scores (50 percent or greater increase) in a statistically greater number of women receiving testosterone compared with placebo	No statistically significant difference in adverse effects over 28 weeks (12 weeks of active treatment)	Placebo-controlled, prospective, crossover study ^{A7}
Methyltestosterone/esterified estrogen (Estratest), 2.5 mg/1.25 mg daily (not FDA approved)	Surgically menopausal women receiving estrogen therapy who have diminished sexual desire or interest as measured by questionnaires or scales	Improved sexual interest or desire score	10 percent of women in the treatment arm discontinued therapy because of adverse events, compared with 2 percent in the placebo arm; increased incidence of weight gain, nervousness, and vaginitis over eight weeks of treatment	Small (n = 102), double-blind RCT ^{A8}
Sildenafil (Viagra), 25 or 50 mg, taken one hour before intercourse (not FDA approved for use in women)	Premenopausal women with female sexual arousal disorder	Increased arousal, enjoyment, satisfaction, frequency of intercourse, and sexual fantasies compared with placebo (no difference between 25- and 50-mg doses); with both doses, frequency of orgasm was statistically more than baseline and placebo, but placebo also demonstrated a statistically significant increase from baseline	Vision problems (two patients receiving sildenafil, one receiving placebo) and headache (no difference between groups); two patients receiving sildenafil withdrew from the trial for fear of adverse events	Blinded, prospective, crossover study ^{A9}
Sildenafil, 50 mg, taken one hour before sexual activity	Postmenopausal women self-referred for sexual dysfunction	No significant improvement in sexual function	Clitoral discomfort or hypersensitivity, dizziness, headache, dyspepsia	Open-label study of 33 women; not placebo controlled ^{A10}
Sildenafil, 50 mg, taken one hour before sexual stimulation	Naturally postmenopausal women receiving estrogen therapy who have female sexual arousal disorder and difficulty with orgasm	No improvement in arousal or orgasm	Hot flashes, headache, and dizziness with sildenafil	Double-blind, placebo-controlled, crossover study ^{A11}

Table continues

Online Table A. (continued)

<i>Therapy/dosage</i>	<i>Population</i>	<i>Effects</i>	<i>Adverse effects</i>	<i>Evidence</i>
Sildenafil, 50 mg, taken one hour before sexual activity	Postmenopausal women receiving hormone therapy (if naturally menopausal) who have female sexual arousal disorder or other sexual dysfunction	No effect in women with female sexual arousal disorder plus diminished sexual interest or desire; increase in sexual arousal, satisfaction with sexual activity, and ability to achieve orgasm in women with female sexual arousal disorder alone; strong placebo response	Headache, hot flashes, rhinitis, nausea, vision problems	Double-blind RCT ^{A12}
Sildenafil, 10 to 100 mg, taken one hour before sexual activity	Pre- and postmenopausal women (some receiving hormone therapy) who have female sexual arousal disorder	No difference in effectiveness between sildenafil and placebo	Headache, hot flashes, rhinitis, nausea, vision problems, dyspepsia	Double-blind RCT ^{A13}
Sildenafil, 100 mg, taken one hour before sexual intercourse	Premenopausal women with type 1 diabetes and female sexual arousal disorder	Increased sexual desire, frequency of orgasm, enjoyment, satisfaction, and frequency of sexual fantasies with sildenafil compared with placebo; statistically significant increase in frequency of intercourse from baseline (no difference between groups)	Headache, nausea, vision problems	Double-blind, placebo-controlled, crossover study ^{A14}
Sildenafil, 50 mg, taken one hour before sexual stimulation	Premenopausal women with spinal cord injury (neurogenic sexual dysfunction)	Small but statistically significant increase in subjective arousal with sildenafil compared with placebo	Hot flashes, headache, vision problems, fatigue	Double-blind, placebo-controlled, crossover study ^{A15}
Sildenafil, 50 mg, taken one hour before sexual activity, with option to adjust dose to 25 or 100 mg	Premenopausal women with multiple sclerosis and symptoms of sexual dysfunction	Self-reported improvement in lubrication and sensation; no improvement in orgasmic capacity or desire	Not reported	Double-blind, placebo-controlled, crossover study with optional open-label extension phase ^{A16}
Tadalafil (Cialis), 20 mg, or vardenafil (Levitra), 10 mg, taken before sexual activity (not FDA approved for use in women)	Women receiving serotonin-enhancing medications (SSRIs, benzodiazepines) that are causing decreased sexual interest or desire or anorgasmia	Reversal of sexual adverse effects from serotonin-enhancing medications	No adverse effects over five to 11 months of treatment	Case series ^{A17} ; case report ^{A18}
Bupropion (Wellbutrin), 300 mg daily, with option to adjust dosage to 450 mg	Premenopausal women with diminished sexual interest or desire	Increased arousal, orgasm completion, satisfaction with bupropion (on one of two measures); no statistically significant increase in desire; improvements were not consistent across both measurements used, and response peaked at day 84 (of 112)	Not reported, high attrition rate	Double-blind RCT; underpowered; funded by bupropion manufacturer ^{A19}

Table continues

Online Table A. (continued)

Therapy/dosage	Population	Effects	Adverse effects	Evidence
Bupropion, 150 or 300 mg daily	Nondepressed women and men with orgasmic dysfunction	Women reported increased satisfaction and ability to reach orgasm; significant placebo response	Headache, insomnia, irritability, anxiety, bizarre dreams, nausea, vomiting, dizziness, dry mouth, edema, decreased short-term memory, decreased appetite, racing heartbeat	Single-blind, crossover study ^{A20}

FDA = U.S. Food and Drug Administration; RCT = randomized controlled trial; SSRI = selective serotonin reuptake inhibitor.

Information from references:

- A1. Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. *N Engl J Med.* 2000;343(10):682-688.
- A2. Braunstein GD, Sundwall DA, Katz M, et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. *Arch Intern Med.* 2005;165(14):1582-1589.
- A3. Simon J, Braunstein G, Nachtigall L, et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. *J Clin Endocrinol Metab.* 2005;90(9):5226-5233.
- A4. Davis SR, van der Mooren MJ, van Lunsen RHW, et al. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. *Menopause.* 2006;13(3):387-396.
- A5. Buster JE, Kingsberg SA, Aguirre O, et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. *Obstet Gynecol.* 2005;105(5 pt 1):944-952.
- A6. Shifren JL, Davis SR, Moreau M, et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. *Menopause.* 2006;13(5):770-779.
- A7. Goldstat R, Briganti E, Tran J, Wolfe R, Davis SR. Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. *Menopause.* 2003;10(5):390-398.
- A8. Warnock JK, Swanson SG, Borel RW, Zipfel LM, Brennan JJ. Combined esterified estrogens and methyltestosterone versus esterified estrogens alone in the treatment of loss of sexual interest in surgically menopausal women. *Menopause.* 2005;12(4):374-384.
- A9. Caruso S, Intelisano G, Lupo L, Agnello C. Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, crossover, placebo-controlled study. *BJOG.* 2001;108(6):623-628.
- A10. Kaplan SA, Reis RB, John IJ, et al. Safety and efficacy of sildenafil in postmenopausal women with sexual dysfunction. *Urology.* 1999;53(3):481-486.
- A11. Basson R, Brotto LA. Sexual psychophysiology and effects of sildenafil citrate in oestrogenised women with acquired genital arousal disorder and impaired orgasm: a randomized controlled trial. *BJOG.* 2003;110(11):1014-1024.
- A12. Berman JR, Berman LA, Toler SM, Gill J, Haughie S. Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: a double blind, placebo controlled study. *J Urol.* 2003;170(6 pt 1):2333-2338.
- A13. Basson R, McInnes R, Smith MD, Hodgson G, Koppiker N. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. *J Womens Health Gen Based Med.* 2002;11(4):367-377.
- A14. Caruso S, Rugolo S, Agnello C, Intelisano G, Di Mari L, Cianci A. Sildenafil improves sexual functioning in premenopausal women with type 1 diabetes who are affected by sexual arousal disorder: a double-blind, crossover, placebo-controlled pilot study. *Fertil Steril.* 2006;85(5):1496-1501.
- A15. Sipski ML, Rosen RC, Alexander CJ, Hamer RM. Sildenafil effects on sexual and cardiovascular responses in women with spinal cord injury. *Urology.* 2000;55(6):812-815.
- A16. DasGupta R, Wiseman OJ, Kanabar G, Fowler CJ. Efficacy of sildenafil in the treatment of female sexual dysfunction due to multiple sclerosis. *J Urol.* 2004;171(3):1189-1193.
- A17. Ashton AK, Weinstein W. Tadalafil reversal of sexual dysfunction caused by serotonin enhancing medications in women. *J Sex Marital Ther.* 2006;32(1):1-3.
- A18. Ashton AK, Vardenafil reversal of female anorgasmia. *Am J Psychiatry.* 2004;161(11):2133.
- A19. Segraves RT, Clayton A, Croft H, Wolf A, Warnock J. Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women. *J Clin Psychopharmacol.* 2004;24(3):339-342.
- A20. Modell JG, May RS, Kathou CR. Effect of bupropion SR on orgasmic dysfunction in nondepressed subjects: a pilot study. *J Sex Marital Ther.* 2000;26(3):231-240.